JAK Inhibitors Taking on Psoriatic Arthritis
- 19 October 2017
- journal article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 377 (16), 1582-1584
- https://doi.org/10.1056/nejme1709907
Abstract
Psoriasis is a chronic inflammatory skin disease that affects 2 to 4% of the population.1 Inflammatory arthritis develops in approximately 30% of patients with psoriasis and can have a major effect on activities of daily living and quality of life.2 Peripheral joint involvement in patients with psoriatic arthritis can be oligoarticular or polyarticular and can cause joint destruction. Several medications are used to treat psoriatic arthritis, and the choice of agent and the timing of administration in the course of the disease depend on disease manifestations, their severity, and prognostic factors.2 Therapy typically involves the sequential use of nonsteroidal antiinflammatory . . .Keywords
This publication has 8 references indexed in Scilit:
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF InhibitorsThe New England Journal of Medicine, 2017
- Tofacitinib or Adalimumab versus Placebo for Psoriatic ArthritisThe New England Journal of Medicine, 2017
- Psoriatic ArthritisThe New England Journal of Medicine, 2017
- Secukinumab: A New Treatment Option for Psoriatic ArthritisRheumatology and Therapy, 2016
- Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseasesNature Reviews Rheumatology, 2015
- Psoriasis prevalence among adults in the United StatesJournal of the American Academy of Dermatology, 2014
- Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potentialTherapeutic Advances in Musculoskeletal Disease, 2013
- Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trialArthritis & Rheumatism, 2007